Menopause syndrome classification

Telling states apart5

• Reporting and selection may create apparent menopause syndromes from partly independent disorders

  Where this hypothesis actsAcross menopause stages and randomized endocrine and nonendocrine treatment assignments

  What is proposedTest whether syndrome labels add predictive value for treatment selection

  With whatInstrument or assay

  HowCompare frozen labels with baseline component severity and clinical modifiers using randomized treatments, objective endpoints and a prespecified equivalence margin

  Possible resultExpected absence of added treatment-selection value or a reproducible shared response factor

  2026-10-03

• Sampling and diagnostic pooling may create an apparent hormone-linked functional syndrome

  Where this hypothesis actsPerimenopausal participants with apparent endocrine variability-associated functional deterioration

  What is proposedDistinguish a proposed shared syndrome from distinct disorders and sampling artifacts

  With whatInstrument or assay

  HowUse dense phase-aware sampling, disorder-specific analysis and external replication, alongside randomized endocrine and downstream treatment contrasts

  Possible resultExpected failure to replicate a shared syndrome, with functional benefit attributable to indicated downstream treatment

  2026-10-03

• Random physiological fluctuations may create apparent menopause response types

  Where this hypothesis actsAcross reproductive stages and assigned endocrine or nonendocrine perturbations

  What is proposedDistinguish continuous physiological states from stable response types

  With whatInstrument or assay

  HowCompare a frozen first-passage model with fixed syndrome labels using repeated recordings and responses to randomized endocrine, nonendocrine and mild thermal perturbations

  Possible resultExpected prediction of event timing and treatment effects without added treatment-selection value from fixed labels

  2026-10-03

• Inherited regulatory combinations may create distinct menopause treatment-response types

  Where this hypothesis actsAcross menopausal stage transitions and independent cohorts

  What is proposedTest whether regulatory genotype identifies distinct treatment-response types

  With whatInstrument or assay

  HowCompare a prespecified regulatory-genotype classifier with flexible continuous baseline models across stage transitions and independent cohorts

  Possible resultExpected reproducible endocrine-versus-nonendocrine treatment interaction beyond continuous baseline models

  2026-10-03

• Internal biological phase may determine menopause treatment response

  Where this hypothesis actsWhen predicting treatment responses across biological phases during menopause

  What is proposedTest syndrome labels against a continuous circular phase-response model

  With whatInstrument or assay

  HowCompare a frozen circular phase-response model with syndrome labels for predicting held-out responses to randomized treatment timing

  Possible resultExpected better prediction of held-out treatment response from internal phase than from syndrome labels

  2026-10-03